Novo Nordisk to Invest Dkk 15.9 Billion in Expanding Manufacturing Facilities in Hillerød, Denmark
Monday, June 12, 2023
Novo Nordisk has recently announced a significant investment of 15.9 billion Danish kroner to expand its existing Active Pharmaceutical Ingredient (API) production facility in Denmark. This expansion aims to cater to the growing demand for medications in the field of serious chronic diseases. Coinciding with the company's 100th anniversary, this investment demonstrates Novo Nordisk's commitment to its Danish roots, as more than half of its global workforce of 21,000-plus employees are based in Denmark.
The expansion in Hillerød, Denmark, will create additional production capacity and enhance Novo Nordisk's ability to meet future market demands. It will serve as a key enabler for the company to develop its future clinical late-phase product portfolio. Henrik Wulff, the executive vice president of Product Supply, Quality & IT, emphasized the importance of this investment in delivering essential medicines to patients worldwide. He also expressed gratitude to the Danish Government and Parliament for their support in ensuring good infrastructure and supplies, enabling the company's production capacity expansion.
The new facility will cover an area of approximately 65,000m2 and will be designed as a multi-product facility, allowing for flexibility and accommodating new processes. It will incorporate state-of-the-art technology and provide a modern and efficient working environment. The construction will prioritize high-quality production while focusing on reducing water and energy consumption in an environmentally sustainable manner.
Construction has already begun, and the facility is expected to commence API production by early 2029. Once completed and fully equipped, the project is anticipated to create 340 new jobs. Novo Nordisk's investment reaffirms the importance of Hillerød and Denmark as integral parts of the company's global footprint and its commitment to serving patients with serious chronic diseases worldwide.
In summary, Novo Nordisk's significant investment in expanding its API production facility in Denmark demonstrates its dedication to meeting future market demands and developing vital medications for patients with serious chronic diseases. The project will not only increase production capacity but also contribute to the local economy by creating new jobs. Novo Nordisk recognizes the support of the Danish Government and Parliament in facilitating infrastructure development, allowing the company to expand its production capabilities and benefit patients worldwide.
